Title |
Penehyclidine hydrochloride: a potential drug for treating COPD by attenuating Toll-like receptors
|
---|---|
Published in |
Drug Design, Development and Therapy, November 2012
|
DOI | 10.2147/dddt.s36555 |
Pubmed ID | |
Authors |
Hong-Tao Xiao, Zhi Liao, Rong-Sheng Tong |
Abstract |
The aim of this review was to evaluate and summarize the available scientific information on penehyclidine hydrochloride (PHC) for the treatment of chronic obstructive pulmonary disease (COPD) as a result of its ability to attenuate Toll-like receptors. Penehyclidine hydrochloride is an anticholinergic drug manufactured in China, with both antimuscarinic and antinicotinic activity. PHC is used widely in the clinic as a reversal agent in cases of organic phosphorus poisoning and soman poisoning, but also may also have an important role as a bronchodilator in the treatment of obstructive airway disease, including asthma and, in particular, COPD. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Canada | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 10 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 2 | 20% |
Student > Bachelor | 1 | 10% |
Student > Master | 1 | 10% |
Professor | 1 | 10% |
Professor > Associate Professor | 1 | 10% |
Other | 1 | 10% |
Unknown | 3 | 30% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 5 | 50% |
Chemistry | 1 | 10% |
Unknown | 4 | 40% |